Amicus Therapeutics Inc. (NASDAQ:FOLD) is one of the 13 hot stocks to buy with the highest upside potential. On January 27, TD Cowen analyst Ritu Baral maintained the firm’s Hold rating on Amicus Therapeutics Inc. (NASDAQ:FOLD), as well as the $14.50 price target on the stock. Amicus’s pre-announced fourth-quarter and full-year 2025 total product revenue were modestly above expectations, according to TD Cowen, with Fabry disease medication Galafold delivering a clear outperformance versus consensus estimate ...

Core Viewpoint - Wave Life Sciences Ltd. (NASDAQ:WVE) is identified as a promising investment opportunity with significant upside potential, particularly driven by its obesity medication, WVE-007, which is expected to generate substantial sales and contribute significantly to the company's valuation [1][2]. Group 1: Analyst Ratings and Price Targets - BofA initiated coverage of Wave Life Sciences with a Buy rating and a price target of $38, highlighting WVE-007 as a key value driver, projected to peak at over $11 billion in sales [1]. - Canaccord Genuity raised its price target for Wave Life Sciences to $43 from $40 while maintaining a Buy rating, following the company's announcement of regaining full rights to WVE-006 from GSK [2]. - H.C. Wainwright reiterated a Buy rating with a price target of $30, emphasizing that the return of rights from GSK allows Wave Life to operate independently and focus on smaller, rarer conditions [2]. Group 2: Company Overview - Wave Life Sciences is a clinical-stage biotechnology company that specializes in developing proprietary RNA medicines and has a diverse pipeline targeting various therapeutic areas [3].

Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") announced today that it has closed a $2.8 million shares-for-interest private placement with an immediate family member (the "Subscriber") of Resverlogix's Chairman and CEO. Under the terms of the shares-for-interest transaction, the Subscriber subscribed for 28,000,000 common shares at CAD$0.10 per share for aggregate proceeds of CAD$2.8 million. After giving effect to the transaction, the Subscriber hold ...

Core Viewpoint - Noveris Health Sciences Inc. has provided additional disclosure regarding the issuance of convertible debentures approved by shareholders, which are part of debt settlement transactions [1][2]. Convertible Debentures - The Company issued a convertible debenture of CAD $1,309,836 to CEO David Joshua Bartch for unpaid management fees on October 14, 2025 [3]. - The Bartch Convertible Debenture matures one year from issuance and is convertible after four months at a price based on the greater of the 20-day trailing volume-weighted average trading price or the minimum conversion price set by the Canadian Securities Exchange [4]. - A second convertible debenture was issued to Pioneer Garage Limited for a total of CAD $7,878,792, which includes amounts for invoices paid on behalf of the Company and equity consideration [6]. Potential Dilution and Control Implications - The Company currently has 1,235,061 common shares outstanding [7]. - Assuming a conversion price of CAD $0.185, full conversion could lead to approximately 50,903,321 common shares outstanding [8]. - The Bartch Convertible Debenture could result in approximately 7,080,195 common shares being issued, while the Pioneer Convertible Debenture could lead to approximately 42,588,065 common shares being issued, totaling around 49,668,260 shares upon full conversion [9]. Continued Listing Requirements - If the convertible debentures are fully converted, the Company may not meet the CSE's Continued Listing Requirements, which could lead to a review and potential suspension or delisting [11]. Related Party Transactions - The issuance of the convertible debentures constitutes related party transactions under MI 61-101, with exemptions from formal valuation requirements due to financial difficulty [12].

RGNX Stockholder Alert: Robbins LLP Remind Investors of the Class Action Lawsuit Against REGENXBIO, Inc. [Accessibility Statement] Skip NavigationSAN DIEGO, Feb. 18, 2026 /PRNewswire/ -- [Robbins LLP] reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026. REGENXBIO is a clinical-stage biotechnology company providing gene therapies that deliver functional genes t ...

Core Viewpoint - Twist Biosciences is discussing a license agreement for its B-Body bispecific technology platform during a conference call, indicating a strategic move to enhance its product offerings and market position [1][2]. Group 1: Company Overview - The conference call features key executives including Dr. Emily Leproust (CEO), Adam Laponis (CFO), Dr. Patrick Finn (President and COO), and Dr. Colby Souders (CSO), highlighting the leadership team's involvement in the company's strategic initiatives [3]. - The press release regarding the license agreement was made available on the company's website, demonstrating transparency and communication with stakeholders [2]. Group 2: Conference Call Details - The call is being recorded and will be archived in the Investors section of the company's website for two weeks, ensuring that interested parties can access the information later [3]. - Participants are encouraged to limit their questions to one during the Q&A session, promoting an orderly discussion [3].

Summary of CRISPR Therapeutics Conference Call Company Overview - **Company**: CRISPR Therapeutics (NasdaqGM:CRSP) - **Event**: Virtual Oncology Leadership Summit - **Date**: February 18, 2026 Key Points Industry Focus - CRISPR Therapeutics is engaged in multiple disease areas, with a strong focus on oncology, cardiovascular diseases, autoimmune diseases, and Type 1 diabetes [3][4] Oncology Programs - **ZugoCell (formerly CTX112)**: A next-generation allogeneic CAR-T therapy targeting CD19, designed to improve potency and safety compared to earlier generations [4][5] - **Allogeneic CAR-T**: Made from healthy donor-derived cells, with advanced edits to enhance efficacy and safety, aiming for autologous-like performance [5][6] Key Edits in ZugoCell - **Beta-2M Knockout**: Prevents immune system from recognizing allogeneic cells as foreign, enhancing persistence [8][9] - **RGNASE1 Knockout**: Retains a naive T cell phenotype, allowing for better expansion and reduced exhaustion [10][11] - **TGF-beta Receptor 2 Knockout**: Prevents exhaustion of CAR-T cells, enhancing potency [10][11] Clinical Strategy - **Autoimmune Diseases**: Rapidly enrolling patients for indications like lupus, myositis, and scleroderma, with plans to expand further [17][18] - **Oncology**: Aiming for high complete response (CR) rates and durability, with initial CR rates for ZugoCell reaching nearly 70% [20][21] Regulatory Pathway - Parallel development in oncology and autoimmune indications, with discussions with regulators expected to guide future trials [27][28] Pricing Strategy - Targeting a price point of around $200K for allogeneic CAR-T therapies, significantly lower than current autologous therapies priced at $350K-$400K [52][53] In Vivo CAR-T Development - Developing both transient and permanent CAR-T therapies using LNP-mediated delivery, with a focus on safety and efficacy [54][55] - Permanent CARs could potentially eliminate tumors with a single injection, offering a significant advancement in oncology [56][57] Market Opportunities - Significant potential in both U.S. and international markets, particularly in regions where autologous therapies are not feasible due to cost and availability [48][49] Future Directions - Continued focus on data collection and analysis in both oncology and autoimmune spaces, with a strong emphasis on achieving long-term remissions and safety [31][32][39] Conclusion - CRISPR Therapeutics is positioned to make significant advancements in both oncology and autoimmune therapies through innovative CAR-T technologies, with a clear strategy for regulatory approval and market entry.

Core Insights - Halozyme Therapeutics (HALO) is positioned as a high-quality growth story with a scalable, royalty-driven platform that is approaching a significant earnings inflection point [1] - The company is expected to see a notable increase in FY25 earnings, indicating strong future potential [1] Company Overview - Halozyme Therapeutics focuses on innovative biotechnology solutions, particularly in drug development [1] - The company aims to reshape treatment paradigms through unique mechanisms of action and first-in-class therapies [1] Analyst Background - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, which informs their investment analysis [1] - The analyst has been active in the biotech investment space for five years, focusing on identifying promising companies at various development stages [1] Research Approach - The research emphasizes evaluating the scientific basis of drug candidates, competitive landscape, clinical trial design, and market opportunities [1] - Financial fundamentals and valuation are also key components of the analysis, aiming to provide a comprehensive understanding of the biotech sector [1]

Core Viewpoint - MindBio Therapeutics Corp. is raising up to $650,000 through a non-brokered private placement to enhance its drug and alcohol intoxication detection technology for the mining industry [1][3]. Group 1: Offering Details - The Company will offer up to 1,083,333 units at a price of $0.60 per unit, aiming for gross proceeds of up to $650,000 [2]. - Each unit consists of one common share and one share purchase warrant, with the warrant allowing the purchase of an additional share at $0.80 for 36 months, subject to accelerated expiry conditions [2]. - The Offering is subject to final board and regulatory approvals, and all securities will have a four-month-and-one-day resale restriction [4]. Group 2: Use of Proceeds - The net proceeds from the Offering will be used to accelerate the development and deployment of proprietary hardware and edge technology for remote use of the intoxication detection solution in mining [3]. - The funds will also support the recruitment of specialized personnel and general working capital purposes [3]. Group 3: Company Overview - MindBio is a biotechnology company focused on commercializing AI prediction technologies for drug and alcohol intoxication detection through voice analysis, utilizing over 50 million data points for accuracy [6]. - The Company is in the process of expanding its prediction tool to cover other types of intoxication for both consumer and enterprise applications [6].

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors [1] - The investing group provides insights such as buy and sell ratings, product sales forecasts for major pharmaceutical companies, integrated financial statements, discounted cash flow analysis, and market-specific analyses [1]